Acquired haemophilia - Nordic guidelines
1
Summary
2
Diagnosis
2.1
Incidence and co-morbidity
2.2
Symptoms and signs and clinical course
2.3
Laboratory screening methods
2.4
Specialized laboratory methods
2.4.1
Blood sampling and transport
2.4.2
Testing at the coagulation laboratory
2.5
Specific methods
2.6
Characteristics of the autoantibodies
2.7
Recommendations
3
Treatment of bleeding
3.1
Principles
3.2
Specific treatments
3.2.1
Bypassing agents
3.2.2
Factor concentrates
3.2.3
Porcine FVIII
3.2.4
Tranexamic acid
3.2.5
Desmopressin
3.2.6
Emicizumab (Hemlibra®)
3.2.7
Local treatment
3.3
Pre- and perioperative management
3.4
Recommendations
4
Eradication therapy
4.1
General aspects
4.2
Corticosteroids, cyclophosphamid and rituximab
4.3
Azathioprine and ciclosporine
4.4
Human immunoglobulin for intravenous use (IVIG)
4.5
Factor VIII concentrate
4.6
Immunoadsorption/MBMP
4.7
Relapse
4.8
Recommendations
References
Acquired haemophilia - Nordic guidelines
Acquired haemophilia - Nordic guidelines
Published online
Last updated: December 2020
Next update: 2021